샘플 요청 목록

 카트 문의
시장보고서
상품코드
1792801

세계의 비낭포성 섬유증 기관지확장증 시장

Non-Cystic Fibrosis Bronchiectasis
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 396 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

비낭포성 섬유증 기관지확장증 세계 시장은 2030년까지 45억 달러에 달할 전망

2024년에 36억 달러로 추정되는 비낭포성 섬유증 기관지확장증 세계 시장은 2024년부터 2030년까지 CAGR 3.8%로 성장하여 2030년에는 45억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 외과 치료는 CAGR 5.2%를 기록하며 분석 기간 종료시에는 13억 달러에 달할 것으로 예측됩니다. 물리요법 치료 분야의 성장률은 분석 기간 동안 CAGR 2.3%로 추정됩니다.

미국 시장은 9억 7,970만 달러로 추정, 중국은 CAGR 7.3%로 성장 예측

미국의 비낭포성 섬유증 기관지확장증 시장은 2024년에 9억 7,970만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 9억 2,090만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.3%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.5%와 3.0%로 예측됩니다. 유럽에서는 독일이 CAGR 2.2%로 성장할 것으로 예측됩니다.

세계의 비낭포성 섬유증 기관지확장증 시장 - 주요 동향과 촉진요인 정리

질병 인식은 어떻게 임상적 인식을 촉진하는가?

비낭포성 섬유증 기관지확장증은 비가역적인 기도 확장, 잦은 감염, 지속적인 가래 분비를 특징으로 하는 만성 호흡기질환입니다. COPD, 천식, 재발성 호흡기 감염 등과 증상이 중복되어 진단되지 않는 경우가 많습니다. 최근 영상 진단, 특히 고해상도 CT 스캔의 발전으로 기관지확장증은 별도의 질환으로 인식되고 있습니다. 폐 전문의와 일반 의사들 사이에서 인지도가 높아짐에 따라, 더 많은 사례들이 확인되고 정확하게 관리되고 있습니다.

지속적인 의학교육과 업데이트된 임상 가이드라인은 인지도 향상에 매우 중요한 역할을 하고 있습니다. 현재 의사들은 호흡기 증상이 반복되는 환자에게 기관지확장증을 고려하는 경향이 강해지고 있습니다. 또한, 환자 교육 캠페인과 호흡기학회는 만성 기침과 가래가 있는 사람들에게 진찰을 받도록 촉구하여 질병의 조기 발견을 더욱 촉진하고 있습니다.

질병 관리에서 어떤 치료 혁신이 일어나고 있는가?

비낭포성 섬유증 기관지확장증 치료는 기존에는 기도확보 기술, 항생제, 악화관리가 주를 이루었습니다. 그러나 몇 가지 새로운 치료법이 개발되고 있습니다. 흡입용 마크로리드 및 장시간 작용하는 항생제는 호흡기 미생물 관리를 개선하면서 전신 노출을 최소화할 수 있도록 개선되고 있습니다. 또한, 점액 활성제 및 고삼투압 식염수 제제는 보다 효과적인 점액 제거를 위해 조정되고 있습니다.

호중구 경로를 조절하도록 설계된 표적 항염증제 및 생물학적 제제 연구도 진행 중입니다. 이러한 치료는 숙주의 방어력을 손상시키지 않으면서 만성 염증을 감소시키는 것을 목표로 합니다. 또한, 새로운 비침습적 인공호흡기 및 기도 확보 장치가 등장하여 맞춤형 호흡 지원을 제공하고 환자의 삶의 질을 향상시키고 있습니다. 악화 빈도를 줄이고 폐 기능을 촉진하기 위해 감시하에 운동과 폐 재활 등의 지원 프로그램이 치료 요법에 포함되고 있습니다.

왜 환자 중심의 다학제 진료 모델이 부상하고 있는가?

비낭포성 섬유증 기관지확장증을 효과적으로 관리하기 위해서는 포괄적이고 환자 중심의 접근이 필요합니다. 호흡기내과 전문의, 물리치료사, 감염내과 전문의, 영양사 등 다학제 진료팀이 호흡기 클리닉과 케어센터의 표준이 되고 있습니다. 이 팀은 기도 확보 계획, 항생제 요법, 영양 상담, 합병증 관리 등을 조정하여 결과를 최적화합니다.

디지털 케어 툴도 환자 지원을 강화하고 있습니다. 모바일 앱은 증상, 복약 순응도, 물리치료 루틴을 추적하는 데 도움이 됩니다. 원격의료 상담 및 원격 모니터링은 악화 시 적시에 개입할 수 있어 병원 재입원을 줄일 수 있습니다. 환자 지원 커뮤니티와 질병 등록은 치료의 연속성과 실제 데이터 수집 노력을 더욱 강화하고 있습니다.

비낭포성 섬유증 기관지확장증 시장의 성장은 몇 가지 요인에 의해 초래됩니다.

임상적 인식의 증가와 영상 진단의 개선으로 발견율이 확대되고 환자층이 확대되고 있습니다. 표적화된 흡입 항생제, 항염증제, 점액제거 요법의 개발로 치료 옵션이 늘어나고 있습니다. 다학제 진료 모델과 디지털 헬스 플랫폼의 통합으로 관리 효과와 환자 참여도가 향상되고 있습니다. 또한, 새로운 생물학적 제제 및 기도 보조 장치를 평가하는 임상시험이 파이프라인의 활성화에 박차를 가하고 있습니다. 공중보건시스템의 만성 호흡기질환 관리에 대한 강조는 기관지확장증 치료 인프라 및 치료에 대한 투자를 지속적으로 지원하고 있습니다.

부문

치료(수술 치료, 물리요법 치료, 백신 치료, 기도 약물요법 치료, 항생제 치료, 기타 치료), 진단(CT 스캔 진단, 기관지경 진단, 흉부 X선 진단, 폐기능 진단, 객담 배양 검사 진단, 혈액 검사 진단, 기타 진단 유형), 최종사용자(병원·진료소 최종사용자, 외래 수술 센터 최종사용자, 기타 최종사용자)

조사 대상 기업 사례

  • Armata Pharmaceuticals
  • AstraZeneca plc
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • CSL Behring
  • GlaxoSmithKline plc
  • Haisco Pharmaceutical Group
  • Infex Therapeutics
  • Insmed Incorporated
  • NovaBiotics
  • Novartis AG
  • Parion Sciences Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Renovion Inc.
  • Sanofi S.A.
  • SolAeroMed Inc.
  • Teva Pharmaceutical Industries
  • Verona Pharma plc
  • Zambon S.p.A.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.25

Global Non-Cystic Fibrosis Bronchiectasis Market to Reach US$4.5 Billion by 2030

The global market for Non-Cystic Fibrosis Bronchiectasis estimated at US$3.6 Billion in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Physiotherapy Treatment segment is estimated at 2.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$979.7 Million While China is Forecast to Grow at 7.3% CAGR

The Non-Cystic Fibrosis Bronchiectasis market in the U.S. is estimated at US$979.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$920.9 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Non Cystic Fibrosis Bronchiectasis Market - Key Trends & Drivers Summarized

How Is Disease Awareness Driving Clinical Recognition?

Non cystic fibrosis bronchiectasis is a chronic respiratory condition marked by irreversible airway dilation, frequent infections, and persistent sputum production. It often goes undiagnosed due to overlapping symptoms with COPD, asthma, or recurrent respiratory infections. Recent improvements in diagnostic imaging, particularly high-resolution CT scans, have led to better recognition of bronchiectasis as a distinct condition. As awareness grows among pulmonologists and general practitioners, more cases are being identified and accurately managed.

Continuing medical education and updated clinical guidelines have played a pivotal role in raising awareness. Physicians are now more likely to consider bronchiectasis in patients with recurrent respiratory symptoms. Patient education campaigns and respiratory societies are also encouraging individuals with chronic cough and sputum to seek evaluation, further supporting earlier detection of the disease.

What Treatment Innovations Are Emerging in Disease Management?

Treatment for non cystic fibrosis bronchiectasis traditionally focuses on airway clearance techniques, antibiotics, and managing exacerbations. However, several novel therapeutic approaches are evolving. Inhaled macrolides and long acting antibiotics are being refined to minimize systemic exposure while improving airway microbiome management. Additionally, mucoactive agents and hyperosmolar saline formulations are being tailored for more effective mucus clearance.

Research into targeted anti inflammatory therapies and biologics designed to modulate neutrophil pathways is also underway. These treatments aim to reduce chronic inflammation without compromising host defense. Furthermore, new non invasive ventilation and airway clearance devices are emerging, providing personalized respiratory support and improving patient quality of life. Supportive programs, such as supervised exercise and pulmonary rehabilitation, are being integrated into treatment regimens to reduce exacerbation frequency and promote lung function.

Why Are Patient-Centric and Multidisciplinary Care Models on the Rise?

Effective management of non cystic fibrosis bronchiectasis requires a comprehensive, patient centric approach. Multidisciplinary teams - including pulmonologists, physiotherapists, infectious disease specialists, and nutritionists - are becoming standard in respiratory clinics and care centers. These teams coordinate airway clearance plans, antibiotic regimens, nutritional counseling, and comorbidity management to optimize outcomes.

Digital care tools have also enhanced patient support. Mobile apps help track symptoms, medication adherence, and physiotherapy routines. Telehealth consultations and remote monitoring enable timely intervention during exacerbations, reducing hospital readmissions. Patient support communities and disease registries are further strengthening treatment continuity and real world data collection efforts.

Growth in the non cystic fibrosis bronchiectasis market is driven by several factors.

Rising clinical awareness and improved diagnostic imaging are expanding detection rates and broadening patient pools. Development of targeted inhaled antibiotics, anti inflammatory agents, and mucus clearing therapies is enhancing treatment options. Integration of multidisciplinary care models and digital health platforms is improving management effectiveness and patient engagement. Additionally, clinical trials evaluating novel biologics and airway support devices are fueling pipeline activity. Greater emphasis on chronic respiratory disease management by public health systems continues to support investment in bronchiectasis care infrastructure and therapies.

SCOPE OF STUDY:

The report analyzes the Non-Cystic Fibrosis Bronchiectasis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment, Other Treatments); Diagnosis (CT Scan Diagnosis, Bronchoscopy Diagnosis, Chest X-Ray Diagnosis, Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Armata Pharmaceuticals
  • AstraZeneca plc
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • CSL Behring
  • GlaxoSmithKline plc
  • Haisco Pharmaceutical Group
  • Infex Therapeutics
  • Insmed Incorporated
  • NovaBiotics
  • Novartis AG
  • Parion Sciences Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Renovion Inc.
  • Sanofi S.A.
  • SolAeroMed Inc.
  • Teva Pharmaceutical Industries
  • Verona Pharma plc
  • Zambon S.p.A.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Non-Cystic Fibrosis Bronchiectasis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates of Chronic Respiratory Conditions Drive Attention Toward Non-Cystic Fibrosis Bronchiectasis
    • Increased Use of High-Resolution CT Scans Enhances Detection and Differentiation of Non-CF Bronchiectasis
    • Growing Geriatric Population and Associated Lung Disorders Spur Market Demand for Long-Term Respiratory Care
    • Rising Incidence of Recurrent Respiratory Infections Throws the Spotlight on Early-Stage Identification and Treatment
    • Expansion of Multidisciplinary Care Models Supports Comprehensive Management of Non-CF Bronchiectasis Patients
    • Adoption of Inhaled Antibiotic Therapies Strengthens Targeted Treatment Strategies for Infection Control
    • Ongoing Clinical Trials Exploring Anti-Inflammatory Agents Stimulate Pipeline Innovation
    • Increased Use of Airway Clearance Devices and Nebulizer Systems Enhances Symptom Management
    • Focus on Reducing Hospital Readmission Rates Drives Use of Maintenance Therapies and Prophylactic Treatments
    • Growing Research into Non-Tuberculous Mycobacterial (NTM) Infections Linked to Bronchiectasis Expands Therapeutic Approaches
    • Integration of Personalized Care Protocols Supports Better Outcomes and Patient Adherence
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Non-Cystic Fibrosis Bronchiectasis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Physiotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Physiotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Physiotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccination Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaccination Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Vaccination Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Airway Pharmacotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Airway Pharmacotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Airway Pharmacotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Antibiotics Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Lung Function Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Lung Function Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Lung Function Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Sputum Culture Test Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Sputum Culture Test Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Sputum Culture Test Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Blood Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Blood Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Blood Tests Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Diagnosis Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for CT Scan Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for CT Scan Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for CT Scan Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Bronchoscopy Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Bronchoscopy Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Bronchoscopy Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Chest X-Ray Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Chest X-Ray Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Chest X-Ray Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: China 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: China 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 101: France Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: France 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: France 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: France 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Germany 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Germany 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Italy 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Italy 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Italy 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 128: UK Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: UK 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 131: UK Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: UK 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: UK 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Spain 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Spain 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Spain 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Russia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Russia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Russia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Australia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Australia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Australia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 185: India Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: India 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 188: India Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: India 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: India 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: South Korea 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: South Korea 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: South Korea 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Argentina 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Argentina 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Argentina 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Brazil 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Brazil 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Brazil 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Mexico 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Mexico 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Mexico 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Rest of Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Rest of Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Iran 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Iran 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Iran 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Israel 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Israel 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Israel 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Saudi Arabia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Saudi Arabia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: UAE 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: UAE 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: UAE 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Africa 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 322: Africa 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 325: Africa 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제